Review reveals the clinical performance of cyclodextrin-based formulations in human participants, highlighting the need for expanded trials to advance polymeric nanocarriers.
This review highlights the current status of cyclodextrin-based formulations tested in human participants, highlighting ongoing clinical research in this area. It provides a comprehensive link between the structure, properties, and clinical applications of these formulations, bridging the gap between medical theory and practical use. The aim of this work is to support the future commercialization of cyclodextrin-based therapies for patient care. Additionally, it emphasizes the need for expanded clinical investigations on cyclodextrin-based formulations, particularly cyclodextrin-based polymers, to pave the way for their successful introduction to the market. This is related to the potential of cyclodextrin-based polymers as advanced drug delivery systems, improving the therapeutic efficacy of numerous drugs. Expanding clinical trials will contribute to the optimization of cyclodextrin-based polymer synthesis, boosting their effectiveness as nanocarriers and facilitating the discovery of new disease treatments. This review also explores the potential of artificial intelligence (AI) to support clinical and medical solutions.
No takes yet. Share an insight, caveat, or question.
Hoti et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: